Last reviewed · How we verify
NCT05333029
Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD
Phase 2 trial testing Allogeneic mesenchymal stromal cells (MSCs) in Graft Versus Host Disease. Withdrawn.
1 December 2024
Quick facts
| Lead sponsor | Molly Gallogly |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 October 2024 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Allogeneic mesenchymal stromal cells (MSCs) — full drug profile →
- Extracorporeal photopheresis (ECP) — full drug profile →
Conditions studied
- Graft Versus Host Disease — all drugs for Graft Versus Host Disease →
Sponsor
Molly Gallogly — full company profile →
Who can join
Adults 18 to 75, any sex, with Graft Versus Host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to see if two treatments (extracorporeal photopheresis and Mesenchymal Stromal Cell (MSC) infusion, can be given safely together, and if they improve the symptoms of a Graft versus Host Disease (GvHD), a complication that can occur in people who undergo stem cell transplant.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease.
Kujawska J, Zeiser R, Gil L. · · 2025 · cited 8× · PMID 39207560 · DOI 10.1007/s00277-024-05952-0 -
Extracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Wu P, Wang Z, Sun Y, Cheng Z, et al · · 2025 · cited 5× · PMID 40133949 · DOI 10.1186/s12951-025-03297-y -
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature.
Kim NH, Hamadani M, Abedin S. · · 2024 · cited 2× · PMID 38973782 · DOI 10.1080/13543784.2024.2377322 -
How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation.
Jiang S, Yan H, Lu X, Wei R, et al · · 2023 · cited 1× · PMID 37207218 · DOI 10.3389/fimmu.2023.1102966 -
The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases.
Deng M, Zhang X, Zhang Y. · · 2025 · PMID 41444972 · DOI 10.1186/s13287-025-04880-8
Verify or expand the search:
- PubMed search for NCT05333029
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graft Versus Host Disease
Currently open trials in the same condition.
- NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
- NCT07006506 — A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant · Phase 2 · recruiting
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
- NCT06705062 — Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment · Phase 3 · recruiting
- NCT06252870 — Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-trans · Phase 2 · recruiting
Other Molly Gallogly trials
Trials by the same sponsor.
- NCT03064867 — Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05333029 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Molly Gallogly
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05333029.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing